Latest Health News
World Neglected Tropical Diseases Day 2026 Observed Globally
Observed on January 30, 2026, this day raises awareness for NTDs affecting over one billion people, with 58 countries eliminating at least one NTD as of early 2026. Progress includes 9 countries validated in 2025 for eliminations like trachoma and sleeping sickness, but funding dropped 41% from 2018-2023.
Dengue Classified as Grade 3 Emergency with Over 14.4 Million Cases in 2024
Dengue surged to exceed 14.4 million cases in 2024, prompting WHO's highest emergency classification and vaccine prequalification. Chikungunya mapping advances amid mosquito-borne spread to new regions due to climate change.
New Cochrane evidence gap maps guide research to address rising cases driven by global warming.
Breakthrough Sepsis Drug STC3141 Succeeds in Phase II Trial
Australian-developed carbohydrate-based drug STC3141 reduced sepsis severity in a Phase II trial with 180 patients in China. It calms dangerous immune reactions causing organ failure, meeting key endpoints with no current anti-sepsis therapy available.
Phase III trials planned, potentially reaching market soon to save millions of lives.
Clascoterone 5% Shows Significant Hair Growth in Male Androgenetic Alopecia
January 2026 top dermatology article reports clascoterone 5% cream promotes hair growth with minimal systemic exposure and good safety. Evolving biologics for hidradenitis suppurativa (HS) like secukinumab and bimekizumab expand options despite relapse needs.
Apogee's zumilokibart targets IL-13 for asthma and atopic dermatitis, with phase 3 planned for late 2026.
BREAKWATER Trial Updates BRAF-Targeted Regimen for Metastatic Colorectal Cancer
2026 ASCO GI Symposium highlights FOLFIRI backbone with Braftovi and Erbitux, offering neuropathy-free efficacy for BRAF V600E patients. Results show strong efficacy similar to prior FOLFOX combo, a game-changer over chemotherapy alone.
Expected FDA approval soon for this frontline metastatic colorectal cancer treatment.
HERIZON-GEA-01 Trial Improves Survival in HER2-Amplified Gastric Cancer
Ziihera combined with immunotherapy in HERIZON-GEA-01 showed 7-month survival gain in upper GI cancer, a significant advancement. Early positive signals from this HER2-targeted regimen position it for FDA approval within a year.
Biomarker-driven therapies highlighted at 2026 ASCO GI Cancers Symposium.
FDA Grants Breakthrough Designation to Alixorexton for Narcolepsy Type 1
Alkermes' oral orexin 2 receptor agonist alixorexton receives Breakthrough Therapy status based on phase 2 Vibrance-1 data in 92 NT1 patients. Also in development for NT2 and idiopathic hypersomnia with positive phase 1/2 results.
Aims to address unmet needs in excessive daytime sleepiness disorders.
Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies
Cognition Therapeutics' SHIMMER study met primary endpoints in 130 adults with mild-moderate dementia with Lewy bodies. Zervimesine showed favorable clinical improvements, advancing treatment options for this neurodegenerative condition.
Supports further development in psychiatric pipeline updates for January 2026.
Brilaroxazine Shows Promise in Schizophrenia Phase 3 RECOVER Trial
Reviva's brilaroxazine reinforces efficacy on negative symptoms via vocal/speech biomarkers in schizophrenia trials. Targets serotonin/dopamine receptors, supporting clinician outcomes and trial efficiency tools.
Published findings bolster its potential across symptom domains.
PATINA Trial Improves PFS in HR+/HER2+ Metastatic Breast Cancer
ECOG-ACRIN's PATINA trial in NEJM shows palbociclib added to maintenance therapy significantly boosts progression-free survival. Changes standard of care for HR+/HER2+ metastatic breast cancer patients.
Highlights definitive trials' role in validating technologies like FDG-PET.
Spanish Scientists Cure Pancreatic Cancer in Mice Using Triple Therapy
Researchers report curing pancreatic cancer in mice via triple therapy, published in a scientific journal. This approach targets the aggressive cancer, offering hope for human applications.
Represents a potential breakthrough in notoriously hard-to-treat pancreatic malignancies.
US Global Health Funding Stalls Amid Budget Uncertainty
FY26 US budget unresolved on January 30, 2026, delays funding for global health programs under strain. Short-term deal averts shutdown but ties to deportation negotiations heighten risks.
Impacts NTDs and other initiatives reliant on official development assistance.